Economic Evaluation of Adding Daratumumab to Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Economic Evaluation of Adding Daratumumab to Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Lidan Yi,1,* Qiao Liu,1,* Chongqing Tan,1 Xiaomin Wan,1 Xia Luo,1 Yinbo Li,2 Haiying Li,3 Xiaohui Zeng3 1Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, People’s Republic of China; 2Hunan Center for Drug Evaluation and Adverse Reaction Monit...

Full description

Saved in:
Bibliographic Details
Main Authors: Yi L, Liu Q, Tan C, Wan X, Luo X, Li Y, Li H, Zeng X
Format: Article
Language:English
Published: Dove Medical Press 2024-11-01
Series:Risk Management and Healthcare Policy
Subjects:
cost-effectiveness
daratumumab
multiple myeloma
markov model
china
Online Access:https://www.dovepress.com/economic-evaluation-of-adding-daratumumab-to-carfilzomib-and-dexametha-peer-reviewed-fulltext-article-RMHP
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.dovepress.com/economic-evaluation-of-adding-daratumumab-to-carfilzomib-and-dexametha-peer-reviewed-fulltext-article-RMHP

Similar Items